NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
NXP900 show promise in preclinical model of group 4 medulloblastoma
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.
Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.
V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...
